SCHEMBL2894646

SCHEMBL2894646

O=C(NC(NC(=O)c1ncc2nc(-c3cccs3)sc2c1O)C(=O)O)c1ncc2nc(-c3cccs3)sc2c1O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.40
ALDH1A1 P00352 3/20 0.40
GAA P10253 4/20 0.38
MAPT P10636 2/20 0.38
ALOX15 P16050 2/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
HSD17B10 Q99714 1/20 0.38
NPC1 O15118 3/20 0.37
RAB9A P51151 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ERCC1 P07992 3/20 0.37
FEN1 P39748 3/20 0.37
ERCC4 Q92889 3/20 0.37
DNASE1 P24855 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
EGLN1 Q9GZT9 1/20 0.33
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2898413 0.84 EGLN1 (0.38) KDM4EALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL2881067 0.83 EGLN1 (0.52) KDM4EALDH1A1GAAEGLN1
SCHEMBL2893699 0.79 EGLN1 (0.41) NPC1RAB9AEGLN1
SCHEMBL2896782 0.79 EGLN1 (0.41) EGLN1
SCHEMBL2880509 0.75 KDM4E (0.57) KDM4EALDH1A1GAAMAPTHPGD
SCHEMBL2889352 0.74 EGLN1 (0.43) MAPTSMN1; SMN2EGLN1HPGDTACR3
SCHEMBL2886217 0.65 EGLN1 (0.56) EGLN1
SCHEMBL27723247 0.65 EGLN1 (0.53) EGLN1
SCHEMBL2884873 0.64 EGLN1 (0.54) KDM4EGAAEGLN1
SCHEMBL2885331 0.63 EGLN1 (0.51) EGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3124489-B1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2020-07-15 EP disclosed
EP-3124489-A1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS Fibrogen, Inc. (US) 2017-02-01 EP disclosed
EP-2016078-B1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2016-06-15 EP disclosed
US-7696223-B2 [(2-bromo-4-hydroxy-1-phenyl-1H-pyrrolo[2,3-c]pyridine-5-carbonyl)-amino]-acetic acid; modulates the stability and/or activity of hypoxia inducible factor (HIF) FIBROGEN, INC. (US) 2010-04-13 US disclosed
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN2 KDM4E 754/4885ALDH1A1 1047/4885GAA 2236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.